Category: Crypto Hub

Posted on by — Leave a comment

XRP Price: Wall Street Access Arrives as First Spot ETF Launches This Week – CoinCentral

Canary Capital has filed the final paperwork needed to launch the first US spot XRP exchange-traded fund. The company submitted a Form 8A to the Securities and Exchange Commission on Monday night.
Bloomberg senior ETF analyst Eric Balchunas said the filing points to a launch on Wednesday or Thursday. Form 8A filings for Hedera ETFs resulted in those funds launching the next day.
Canary filed 8A for XRP ETF last night, which points to launch tomorrow or Thursday (today is holiday). Thursday was the day we thought they'd be on track for but when they did the 8A for HBAR they launched the next day. Not done deal but all boxes being checked. Stay tuned.. pic.twitter.com/gVt9c3psmu
— Eric Balchunas (@EricBalchunas) November 11, 2025

The Nasdaq needs to certify the listing by 5:30 PM ET on Wednesday. Once that happens, the ETF could start trading Thursday morning.
Canary’s ETF differs from other XRP investment products already available in the US. The fund was filed under the Securities Act of 1933. This allows it to directly hold XRP tokens rather than investing through an offshore company.
Canary Capital is not alone in seeking to launch an XRP ETF. The Depository Trust and Clearing Corporation platform shows several other spot XRP ETFs in the pre-launch phase.
Companies including Bitwise, CoinShares, and Franklin Templeton have XRP ETFs listed on the DTCC. ETF expert Nate Geraci estimates these funds could launch within a couple of weeks.
The end of the government shutdown has cleared regulatory hurdles. This has created a path for multiple XRP ETFs to enter the market.
XRP is currently trading at $2.39. The token faced selling pressure when it reached $2.50 recently.
Technical analysis shows XRP may retest support at $2.38 before attempting another move higher. The Relative Strength Index is approaching overbought levels on lower time frames.
Analysts believe XRP could push toward $3 if the ETF launches proceed as expected. A breakout above $3 could open the door to $4.
$XRP is forming Cup and Handle🚀
This is a massive bullish signal for continuation. Next stop is $3.00+! 🚀 pic.twitter.com/SuloR7L77G
— 𝐊𝐚𝐦𝐫𝐚𝐧 𝐀𝐬𝐠𝐡𝐚𝐫 (@Karman_1s) November 11, 2025

The combined assets under management of these ETFs could quickly surpass $1 billion. This follows a similar pattern to what happened when Bitwise’s spot Solana ETF entered the market.
The new ETFs will provide regulated access to XRP for both retail and institutional investors. These funds offer an alternative to buying XRP directly on crypto exchanges.
The spot ETF structure allows funds to hold actual XRP tokens. This differs from futures-based products that track contracts rather than the underlying asset.
Crypto reporter Eleanor Trent confirmed that Canary’s filing represents the final step before the ETF goes effective. The company is waiting for Nasdaq certification to complete the process.
The launch of multiple XRP ETFs represents a new phase for the token in US markets. Investors will have several regulated options to gain exposure to XRP through traditional brokerage accounts.
📈 Futures & Crypto Trader 🔍 Sharing charts, strategies, & mindset tips to help you level up 🚨 Not Financial Advice Follow on X @Pro_Trader_Edge
TLDR Crypto ETFs saw $1.2 billion in outflows last week, but Solana ETFs received $118…


Never Miss Another Opportunity.
Get hand selected news & info from our Crypto Experts so you can make educated, informed decisions that directly affect your crypto profits!
Type above and press Enter to search. Press Esc to cancel.
BC Game Crypto: 100% Bonus & 400 Free Casino Spins, Claim Here!

source

Posted on by — Leave a comment

Ghanaian Traders expectant of Nibima for Covid-19 treatment – News Ghana

Some traders at the Central Business District (CBD) of Accra on Monday expressed optimism about the Nibima herbal preparation under clinical trial for the treatment of COVID-19.
The herbal medicine Cryptolepis Sanguinolenta, locally known as Nibima was recently approved by Ghana Food and Drugs Authority (FDA) for clinical trials for the treatment of COVID-19.
A visit by the Ghana News Agency (GNA) to some Herbal wholesale and retail shops at Okaishie Drug Lane and the CBD of Accra, the traders expressed confidence that the product would be preferred option to many.
Mr. Meshack Abeka, Sales Manager, Angel Herbal, said demand for the product would be a “hotcake”, adding that he anticipates the possibility of a rush when approved by the FDA for treatment of COVID-19.
“Some Ghanaians often patronizes products based on the big adverts but not necessary its efficacy,” he said.
He also commended the FDA who occasionally visit herbal shops pick some products and re-examine their efficacy to ensure that most of these shop maintain the approved standards.
He claimed that some producers present the right samples to the Authorities for approval but afterward because of monetary considerations reduce the standards for mass production, which they push onto the market.
Another trader at Okaishie told GNA that, that the herbal medicine would be preferred to other vaccine to cure COVID-19 as per traditional belief and norms herbal medicines are the best and have the potency to cure multiple ailment.
Madam Mary Owusu, a trader at the CDB of Accra, said if the herb had been approved, cost element would play a major factor in its patronage as it would be affordable, “apart from affordability, accessibility would also play a critical role.
“I will personally make it mandatory for my family to drink it every morning and evening to prevent contracting the disease”.
Mr. Isaac Obiri, Sales Manager, Kof-Sam Herbal, said “we are waiting for the product, after the trial we will stock our shops to make sure that Ghanaians who needs it get it”.
Ms Joyce Kpentey, Sales Manager, Kingswalk Herbal, assess the commercial value, said “if it is finally approved, it would create a new herbal medicine value chain, it will create jobs, and more people will generate income along the value chain”.
Nibima herbal malaria medicine developed in Ghana by the Centre for Plant Medicine Research in Mampong-Akuapim, which was submitted by researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST) for clinical trial for the treatment of COVID-19 was granted in January 2021 by FDA.

Ghana leading online news portal for executives in Ghana, Africa and around the World

Address: No. 1 Ostwe Close Klannaa St, Box la 478, Accra

Tel: +233 20 189 6055

Email: [email protected]
© 2012-2025 News Ghana All Rights Reserved.

source